Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14144) 14144
Publication (1169) 1169
Newsletter (771) 771
Newspaper Article (559) 559
Book Review (197) 197
Book Chapter (123) 123
Book / eBook (62) 62
Magazine Article (36) 36
Web Resource (23) 23
Dissertation (22) 22
Transcript (12) 12
Conference Proceeding (9) 9
Trade Publication Article (9) 9
Data Set (4) 4
Report (3) 3
Paper (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11597) 11597
male (8178) 8178
female (7980) 7980
middle aged (6982) 6982
adult (6417) 6417
oncology (5712) 5712
aged (5635) 5635
index medicus (5588) 5588
lymphomas (4231) 4231
hematology (4206) 4206
prognosis (3649) 3649
cancer (3569) 3569
non-hodgkins-lymphoma (3314) 3314
chemotherapy (3283) 3283
adolescent (2995) 2995
lymphoma, non-hodgkin - mortality (2650) 2650
antineoplastic combined chemotherapy protocols - therapeutic use (2620) 2620
lymphoma (2591) 2591
treatment outcome (2577) 2577
retrospective studies (2364) 2364
aged, 80 and over (2302) 2302
survival rate (2268) 2268
non-hodgkin's lymphomas (2117) 2117
risk factors (2099) 2099
research (1984) 1984
care and treatment (1945) 1945
mortality (1930) 1930
survival analysis (1849) 1849
transplantation (1767) 1767
disease-free survival (1651) 1651
leukemia (1626) 1626
child (1623) 1623
neoplasm staging (1522) 1522
survival (1519) 1519
rituximab (1472) 1472
health aspects (1398) 1398
follow-up studies (1373) 1373
young adult (1363) 1363
lymphoma, non-hodgkin - drug therapy (1352) 1352
combined modality therapy (1264) 1264
lymphoma, non-hodgkin - pathology (1254) 1254
therapy (1214) 1214
lymphoma, large b-cell, diffuse - mortality (1183) 1183
lymphoma, non-hodgkin - therapy (1178) 1178
immunology (1126) 1126
cyclophosphamide - administration & dosage (1120) 1120
disease (1120) 1120
risk (1093) 1093
child, preschool (1035) 1035
analysis (1009) 1009
patients (993) 993
diagnosis (984) 984
b-cell lymphoma (961) 961
lymphoma - mortality (943) 943
hemic and lymphatic diseases (932) 932
stem cells (924) 924
vincristine - administration & dosage (914) 914
epidemiology (909) 909
incidence (891) 891
time factors (872) 872
non-hodgkin's lymphoma (860) 860
doxorubicin - administration & dosage (857) 857
remission induction (855) 855
tumors (855) 855
antineoplastic combined chemotherapy protocols - adverse effects (835) 835
antineoplastic combined chemotherapy protocols - administration & dosage (829) 829
recurrence (827) 827
transplantation, autologous (792) 792
patient outcomes (755) 755
antineoplastic agents - therapeutic use (747) 747
prednisone - administration & dosage (743) 743
medical research (740) 740
radiotherapy (728) 728
lymphoma, large b-cell, diffuse - drug therapy (727) 727
bone-marrow-transplantation (725) 725
classification (723) 723
non-hodgkin lymphoma (700) 700
non-hodgkin-lymphoma (695) 695
cohort studies (687) 687
animals (666) 666
follicular lymphoma (654) 654
cyclophosphamide (653) 653
age factors (650) 650
t cells (642) 642
public, environmental & occupational health (633) 633
lymphoma, non-hodgkin - epidemiology (629) 629
cancer therapies (623) 623
hematopoietic stem cell transplantation (622) 622
medicine (611) 611
studies (602) 602
medicine, general & internal (597) 597
prospective studies (597) 597
lymphoma, large b-cell, diffuse - pathology (592) 592
kaplan-meier estimate (586) 586
infant (585) 585
pathology (584) 584
expression (571) 571
medical prognosis (558) 558
multivariate analysis (553) 553
article (547) 547
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (48) 48
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Hospital Department (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT Schools - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15011) 15011
Japanese (150) 150
German (144) 144
Spanish (96) 96
French (83) 83
Russian (70) 70
Chinese (55) 55
Italian (52) 52
Polish (34) 34
Portuguese (13) 13
Hungarian (8) 8
Norwegian (8) 8
Czech (7) 7
Dutch (7) 7
Turkish (5) 5
Danish (4) 4
Croatian (3) 3
Hebrew (3) 3
Swedish (3) 3
Bulgarian (2) 2
Finnish (2) 2
Korean (2) 2
Romanian (2) 2
Serbian (2) 2
Ukrainian (2) 2
Afrikaans (1) 1
Arabic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Contributions of HIV to non-hodgkin lymphoma mortality trends in the United States
by Howlader, Nadia and Shiels, Meredith S and Mariotto, Angela B and Engels, Eric A
Cancer Epidemiology Biomarkers and Prevention, ISSN 1055-9965, 09/2016, Volume 25, Issue 9, pp. 1289 - 1296
Background: The human immunodeficiency virus (HIV) epidemic has strongly influenced non-Hodgkin lymphoma (NHL) incidence in the U.S. general population, but... 
POPULATION | RATES | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | CHANGING INCIDENCE | KAPOSIS-SARCOMA | ONCOLOGY | CANCER-RISK | SURVEILLANCE | AIDS | PEOPLE | United States - epidemiology | SEER Program | Humans | Middle Aged | Risk Factors | Antiretroviral Therapy, Highly Active - adverse effects | Male | Mortality - trends | Lymphoma, Large B-Cell, Diffuse - virology | Burkitt Lymphoma - mortality | Incidence | Lymphoma, Large B-Cell, Diffuse - mortality | Young Adult | Lymphoma, AIDS-Related - mortality | Adult | Female | HIV Infections - drug therapy | HIV Infections - mortality | Aged | Lymphoma, AIDS-Related - virology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Contributions of subtypes of non-Hodgkin lymphoma to mortality trends
by Howlader, Nadia and Morton, Lindsay M and Feuer, Eric J and Besson, Caroline and Engels, Eric A
Cancer Epidemiology Biomarkers and Prevention, ISSN 1055-9965, 01/2016, Volume 25, Issue 1, pp. 174 - 179
Background: Non-Hodgkin lymphoma (NHL) comprises distinct tumor subtypes. Although mortality from NHL overall has changed dramatically in the United States... 
UNITED-STATES | B-CELL LYMPHOMA | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | CHANGING INCIDENCE | ONCOLOGY | COLORECTAL-CANCER MORTALITY | ELDERLY PATIENTS | PROSTATE-CANCER | POPULATION-BASED ANALYSIS | FOLLICULAR LYMPHOMA | ACUTE MYELOID-LEUKEMIA | EPIDEMIOLOGIC RESEARCH | United States - epidemiology | SEER Program | Prognosis | Age Factors | Follow-Up Studies | Humans | Lymphoma, Follicular - diagnosis | Lymphoma, Follicular - mortality | Survival Rate | Mortality - trends | Lymphoma, T-Cell, Peripheral - epidemiology | Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology | Incidence | Lymphoma, Large B-Cell, Diffuse - mortality | Lymphoma, Large B-Cell, Diffuse - diagnosis | Lymphoma, Follicular - epidemiology | Lymphoma, T-Cell, Peripheral - diagnosis | Lymphoma, Large B-Cell, Diffuse - epidemiology | Adult | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Neoplasm Staging | Lymphoma, T-Cell, Peripheral - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Histologic Subtypes | Incidence-based mortality | Non-Hodgkin lymphoma tumor subtype trends | Partition mortality trends | SEER Registries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan
by Tseng, Chin-Hsiao
Metabolism, ISSN 0026-0495, 2012, Volume 61, Issue 7, pp. 1003 - 1009
Abstract The objective was to evaluate non-Hodgkin lymphoma (NHL) mortality trends and mortality rate ratios between diabetes patients and the general... 
Endocrinology & Metabolism | ETIOLOGY | WOMEN | METAANALYSIS | NATIONAL COHORT | ENDOCRINOLOGY & METABOLISM | CANCER-RISK | MELLITUS | EPIDEMIOLOGY | Hypoglycemic Agents - therapeutic use | Age Factors | Humans | Middle Aged | Risk Factors | Male | Taiwan - epidemiology | Sex Factors | Aged, 80 and over | Female | Aged | Lymphoma, Non-Hodgkin - mortality | Diabetes Mellitus, Type 2 - drug therapy | Longitudinal Studies | Insulin - therapeutic use | Type 2 diabetes | Diabetics | Mortality | Lymphomas | Non-Hodgkin's lymphomas | Diabetes | Insulin | Health aspects | Risk factors | Tumors | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial
by Lowry, Lisa and Smith, Paul and Qian, Wendi and Falk, Stephen and Benstead, Kim and Illidge, Tim and Linch, David and Robinson, Martin and Jack, Andrew and Hoskin, Peter
Radiotherapy and Oncology, ISSN 0167-8140, 2011, Volume 100, Issue 1, pp. 86 - 92
Abstract Purpose This multicentre, prospective, randomised-controlled trial compared efficacy and toxicity of differing radiotherapy doses in non-Hodgkin... 
Hematology, Oncology and Palliative Medicine | Non-Hodgkin | Radiotherapy | Dose | Lymphoma | RATES | ONCOLOGY | DISEASE | CONSOLIDATION RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CHEMOTHERAPY | BULKY | FIELD RADIATION-THERAPY | Radiotherapy Dosage | Humans | Middle Aged | Aged, 80 and over | Adult | Female | Male | Aged | Lymphoma, Non-Hodgkin - mortality | Lymphoma, Non-Hodgkin - radiotherapy | Clinical trials | Non-Hodgkin's lymphomas
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: A pooled analysis of 1546 patients
by Barta, Stefan K and Xue, Xiaonan and Wang, Dan and Tamari, Roni and Lee, Jeannette Y and Mounier, Nicolas and Kaplan, Lawrence D and Ribera, Josep-Maria and Spina, Michele and Tirelli, Umberto and Weiss, Rudolf and Galicier, Lionel and Boue, Francois and Wilson, Wyndham H and Wyen, Christoph and Oriol, Albert and Navarro, José-Tomás and Dunleavy, Kieron and Little, Richard F and Ratner, Lee and Garcia, Olga and Morgades, Mireia and Remick, Scot C and Noy, Ariela and Sparano, Joseph A
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 19, pp. 3251 - 3262
Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma. We analyzed pooled individual patient data for 1546 patients from 19... 
INFUSIONAL CYCLOPHOSPHAMIDE | B-CELL LYMPHOMA | PHASE-II TRIAL | ACTIVE ANTIRETROVIRAL THERAPY | PLUS RITUXIMAB | CHOP | DOSE-ADJUSTED EPOCH | ORAL COMBINATION CHEMOTHERAPY | HEMATOLOGY | G-CSF | VIRUS-INFECTION STATUS | Doxorubicin - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | HIV - drug effects | Lymphoma, AIDS-Related - mortality | Lymphoma, Non-Hodgkin - complications | Anti-HIV Agents - therapeutic use | HIV Infections - mortality | Lymphoma, AIDS-Related - virology | Lymphoma, Non-Hodgkin - drug therapy | Lymphoma, AIDS-Related - drug therapy | Drug Administration Schedule | Lymphoma, Non-Hodgkin - virology | HIV Infections - virology | Rituximab | Etoposide - therapeutic use | Treatment Outcome | Clinical Trials as Topic | Antiretroviral Therapy, Highly Active | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | HIV Infections - complications | Lymphoma, AIDS-Related - complications | Survival Analysis | Vincristine - therapeutic use | HIV Infections - drug therapy | Lymphoma, Non-Hodgkin - mortality | Infusions, Intravenous | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Plenary Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Non-hodgkin lymphoma in children and adolescents: Progress through effective collaboration, current knowledge, and challenges ahead
by Minard-Colin, Véronique and Brugières, Laurence and Reiter, Alfred and Cairo, Mitchell S and Gross, Thomas G and Woessmann, Wilhelm and Burkhardt, Birgit and Sandlund, John T and Williams, Denise and Pillon, Marta and Horibe, Keizo and Auperin, Anne and Le Deley, Marie-Cécile and Zimmerman, Martin and Perkins, Sherrie L and Raphael, Martine and Lamant, Laurence and Klapper, Wolfram and Mussolin, Lara and Poirel, Hélène A and Macintyre, Elizabeth and Damm-Welk, Christine and Rosolen, Angelo and Patte, Catherine
Journal of Clinical Oncology, ISSN 0732-183X, 09/2015, Volume 33, Issue 27, pp. 2963 - 2974
Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few... 
ADVANCED-STAGE | BURKITT-LYMPHOMA | ONCOLOGY | ACUTE-LYMPHOBLASTIC-LEUKEMIA | FRENCH-SOCIETY | MULTIAGENT CHEMOTHERAPY | MINIMAL DISSEMINATED DISEASE | HIGH-DOSE METHOTREXATE | PEDIATRIC-PATIENTS | BONE-MARROW | LARGE-CELL LYMPHOMA | Pediatrics - trends | Humans | Risk Factors | Survivors | Cooperative Behavior | Treatment Outcome | International Cooperation | Forecasting | Disease-Free Survival | Interdisciplinary Communication | Time Factors | Lymphoma, Non-Hodgkin - therapy | Medical Oncology - trends | Adolescent | Age of Onset | Diffusion of Innovation | Lymphoma, Non-Hodgkin - mortality | Child | Lymphoma, Non-Hodgkin - diagnosis | Index Medicus | Pedi11 | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Incidence and mortality from non‐Hodgkin lymphoma in Europe: The end of an epidemic?
by Bosetti, Cristina and Levi, Fabio and Ferlay, Jacques and Lucchini, Franca and Negri, Eva and La Vecchia, Carlo
International Journal of Cancer, ISSN 0020-7136, 10/2008, Volume 123, Issue 8, pp. 1917 - 1923
Non‐Hodgkin lymphomas (NHL) are among the few neoplasms whose incidence and mortality have been rising in Europe and North America over the last few decades.... 
mortality | non‐Hodgkin lymphoma | incidence | Europe | trends | Non-Hodgkin lymphoma | Trends | Mortality | Incidence | UNITED-STATES | SURVIVAL | RECENT TRENDS | NEOPLASMS | RISK | CLASSIFICATION | non-Hodgkin lymphoma | CANCER | DENMARK | HEPATITIS-C VIRUS | ONCOLOGY | PROJECTIONS | Disease Outbreaks | Humans | Middle Aged | Europe - epidemiology | Adult | Female | Male | Lymphoma, Non-Hodgkin - mortality | Mortality - trends | Lymphoma, Non-Hodgkin - epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
by Flinn, Ian W and Kahl, Brad S and Leonard, John P and Furman, Richard R and Brown, Jennifer R and Byrd, John C and Wagner-Johnston, Nina D and Coutre, Steve E and Benson, Don M and Peterman, Sissy and Cho, Yoonjin and Webb, Heather K and Johnson, David M and Yu, Albert S and Ulrich, Roger G and Godfrey, Wayne R and Miller, Langdon L and Spurgeon, Stephen E
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 22, pp. 3406 - 3413
Idelalisib (GS-1101, CAL-101), an oral inhibitor of phosphatidylinositol 3-kinase-delta, was evaluated in a phase I study in 64 patients with relapsed indolent... 
REFRACTORY INDOLENT | BENDAMUSTINE | CAL-101 | PI3K | HEMATOLOGY | RITUXIMAB | Humans | Middle Aged | Salvage Therapy | Quinazolinones - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Purines - administration & dosage | Neoplasm Grading | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Purines - adverse effects | Purines - therapeutic use | Lymphoma, Non-Hodgkin - drug therapy | Quinazolinones - pharmacokinetics | Purines - pharmacokinetics | Treatment Outcome | Class Ia Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Aged | Lymphoma, Non-Hodgkin - mortality | Quinazolinones - therapeutic use | Quinazolinones - adverse effects | Lymphoma, Non-Hodgkin - diagnosis | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
by Maddocks, Kami and Christian, Beth and Jaglowski, Samantha and Flynn, Joseph and Jones, Jeffery A and Porcu, Pierluigi and Wei, Lai and Jenkins, Cynthia and Lozanski, Gerard and Byrd, John C and Blum, Kristie A
Blood, ISSN 0006-4971, 01/2015, Volume 125, Issue 2, pp. 242 - 248
Ibrutinib has single agent activity of 22% to 68% in relapsed B-cell non-Hodgkin lymphoma (NHL). This study evaluated the safety and efficacy of ibrutinib... 
TRIAL | MANTLE-CELL | 1ST-LINE TREATMENT | B-CELL LYMPHOMA | MULTICENTER | PLUS RITUXIMAB | TARGETING BTK | HEMATOLOGY | INDOLENT | Nitrogen Mustard Compounds - administration & dosage | Pyrimidines - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Rituximab | Male | Nitrogen Mustard Compounds - adverse effects | Young Adult | Maximum Tolerated Dose | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Aged, 80 and over | Adult | Female | Aged | Lymphoma, Non-Hodgkin - mortality | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
by Younes, Anas, Prof and Thieblemont, Catherine, Prof and Morschhauser, Franck, Prof and Flinn, Ian, MD and Friedberg, Jonathan W, Prof and Amorim, Sandy, MD and Hivert, Benedicte, MD and Westin, Jason, MD and Vermeulen, Jessica, MD and Bandyopadhyay, Nibedita, PhD and de Vries, Ronald, MSc and Balasubramanian, Sriram, PhD and Hellemans, Peter, MD and Smit, Johan W, PhD and Fourneau, Nele and Oki, Yasuhiro, MD
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Non-Hodgkin Lymphoma: Diagnosis and Treatment
by Ansell, Stephen M., MD, PhD
Mayo Clinic Proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 8, pp. 1152 - 1163
Abstract Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and clinical behavior. Patients typically present with persistent... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | BURDEN FOLLICULAR LYMPHOMA | PROGRESSION-FREE SURVIVAL | POPULATION-BASED COHORT | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | T-CELL | CHOP PLUS RITUXIMAB | MALT LYMPHOMA | EPSTEIN-BARR-VIRUS | Lymphoma, Non-Hodgkin - mortality | Prognosis | Neoplasm Staging | Lymphoma, Non-Hodgkin - therapy | Humans | Lymphoma, Non-Hodgkin - diagnosis | Complications and side effects | Care and treatment | Stem cells | Transplantation | Non-Hodgkin's lymphomas | Diagnosis | Research | Health aspects | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Prognostic value of event‐free survival at 12 and 24 months and long‐term mortality for non‐Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group
by Provencio, Mariano and Royuela, Ana and Torrente, María and Pollán, Marina and Gómez‐Codina, José and Sabín, Pilar and Llanos, Marta and Gumá, Josep and Quero, Cristina and Blasco, Ana and Aguiar, David and García‐Arroyo, Francisco Ramón and Lavernia, Javier and Martínez, Natividad and Morales, Manuel and Saenz‐Cusi, Álvaro and Rodríguez, Delvys and Calvo, Virginia and Cruz‐Merino, Luis and Cruz, Miguel Ángel and Rueda, Antonio and Spanish Lymphoma Oncology Grp and Spanish Lymphoma Oncology Group
Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3709 - 3716
BACKGROUND Relatively few studies have analyzed the mortality of follicular lymphoma (FL) patients in comparison with a sex‐ and age‐matched general... 
follicular lymphoma | mortality | standard mortality ratio | UNITED-STATES | YOUNG-ADULTS | TRIAL | WOMEN | B-CELL LYMPHOMA | ONCOLOGY | DISEASE | RISK | RITUXIMAB MAINTENANCE | Confidence Intervals | Lymphoma, Follicular - drug therapy | Prognosis | Prospective Studies | Age Factors | Humans | Middle Aged | Kaplan-Meier Estimate | Lymphoma, Follicular - mortality | Male | Antineoplastic Agents - therapeutic use | Case-Control Studies | Cause of Death | Disease-Free Survival | Rituximab - therapeutic use | Time Factors | Spain - epidemiology | Sex Factors | Adult | Female | Young adults | Statistical analysis | Mortality | Sex | Population studies | Lymphoma | Survival | Patients | Confidence intervals | Population | Death | Lymphomas | Adults | Age | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Prognosis and outcome of non-hodgkin lymphoma in primary sjögren syndrome
by Voulgarelis, Michael and Ziakas, Panayiotis D and Papageorgiou, Aristea and Baimpa, Evangelia and Tzioufas, Athanasios G and Moutsopoulos, Haralampos M
Medicine, ISSN 0025-7974, 01/2012, Volume 91, Issue 1, pp. 1 - 9
Sjogren syndrome (SS) has been associated with the development of non-Hodgkin lymphoma (NHL). From a cohort of 584 SS patients followed in our department from... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | THERAPY | MALIGNANT-LYMPHOMA | RITUXIMAB | RISK | GRADE | TISSUE LYMPHOMA | COHORT | CANCER | Lymphoma, Non-Hodgkin - immunology | Prognosis | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Lymphoma, Non-Hodgkin - pathology | Sjogren's Syndrome - mortality | Female | Lymphoma, Non-Hodgkin - mortality | Retrospective Studies | Sjogren's Syndrome - complications | Lymphoma, Non-Hodgkin - diagnosis | Lymphoma, Non-Hodgkin - drug therapy | Lymphoma, Non-Hodgkin - etiology | Usage | Care and treatment | Sjogren's syndrome | Patient outcomes | Non-Hodgkin's lymphomas | Risk factors | Chemotherapy | Causes of | Diagnosis | Health risk assessment | Methods | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights